Mazdutide and Survodutide: GLP-1/Glucagon Dual Agonists
Why add glucagon-receptor activity to a GLP-1 agonist, and how these two compounds differ from tirzepatide and retatrutide.
Mazdutide (IBI362, originally LY3305677) and survodutide (BI 456906) are both dual agonists of the GLP-1 receptor and the glucagon receptor. They sit in a different part of the incretin family from tirzepatide, which pairs GLP-1 with GIP, and from retatrutide, which activates GLP-1, GIP, and glucagon receptors together.
Why add glucagon-receptor activity?
The GLP-1 component reduces appetite and tempers glucose excursions. Glucagon-receptor activation adds effects that GLP-1 alone does not: increased energy expenditure and increased hepatic lipid oxidation. Pairing the two is intended to combine reduced intake with higher energy output while the GLP-1 component offsets the glucose-raising tendency of glucagon.
Published research applications
Because the glucagon receptor is concentrated in liver, these compounds are of particular interest in hepatic-steatosis and metabolic-liver-disease models as well as in obesity and glucose-metabolism models. Both have reached late-stage clinical development in obesity and related indications, and mazdutide in particular has been studied extensively in Chinese populations.
How they compare
Mazdutide and survodutide are GLP-1/glucagon dual agonists. Tirzepatide adds GIP-receptor activity instead of glucagon, and retatrutide combines all three. For protocols asking what glucagon-receptor activity contributes in isolation from GIP signalling, the GLP-1/glucagon pair is the cleaner comparison.
Reconstitution and handling
QSC supplies mazdutide in 10-vial packs of 5 mg and 10 mg vials and survodutide in 10 mg vials, as lyophilized powder. Reconstitute in sterile water per your protocol and refrigerate; keep long-term stock at -20°C.
